Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
British Journal of Haematology|July 1, 2025
Acute kidney injury after chimeric antigen receptor T-cell therapy is associated with inferior survival in patients with relapsed/refractory large B-cell lymphomaJohn Sharp, Qiuhong Zhao, Timothy J Voorhees, et al.
Journal for Immunotherapy of Cancer|August 25, 2021
Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphomaJonathan E Brammer, Zachary Braunstein, Aashish Katapadi, et al.
Blood|March 14, 2022
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AMLH Moses Murdock, Haesook T Kim, Nathan Denlinger, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 4, 2025
Isolated oral CD30+/CD4+ CAR+ T-cell lymphoma in long-term remission after radiotherapyEvandro Bezerra, Ludmila Lupu, Marcos de Lima, et al.
Journal of Hematology & Oncology|March 18, 2025
Second primary malignancies following CAR T-cell therapy in patients with hematologic malignanciesElvira Umyarova, Charles Pei, William Pellegrino, et al.
Research Square|February 23, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Blood Cancer Discovery|July 14, 2026
Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Sumithira Vasu, Nathan Denlinger, No-Joon Song, et al.
Blood Advances|September 12, 2022
Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHLJoanna Zurko, Imran Nizamuddin, Narendranath Epperla, et al.
JCI Insight|February 7, 2023
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapyJoseph H Azar, John P Evans, Madison H Sikorski, et al.
Blood Advances|April 12, 2024
Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphomaNathan Denlinger, No-Joon Song, Xiaoli Zhang, et al.
Pageof 3